Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx Corp demonstrated significant growth with a 30% year-over-year increase in contracted revenue and substantial outperformance in both revenue and earnings per share, signaling strong operational efficiency. The company's evolving role in facilitating digital communication between pharmaceutical companies and healthcare providers positions it favorably in a market increasingly leaning towards digital interactions, leading to anticipated revenue growth in the high teens to low twenties. Moreover, the firm has improved its revenue visibility for 2025, with over 85% clarity on total revenue projections, alongside an EBITDA guidance that exceeds prior consensus, supporting a positive long-term financial outlook.

Bears say

OptimizeRx Corp operates within the U.S. healthcare market, providing digital health messaging to facilitate communication between pharmaceutical companies and healthcare providers. Despite its innovative offerings, the company faces challenges such as increasing competition and potential regulatory hurdles that may impact its market share and profitability. Financially, the firm's revenue growth has been inconsistent, which raises concerns about its long-term sustainability and ability to effectively utilize its resources amidst a fluctuating demand for its services.

OptimizeRx Corp (OPRX) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 4 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.